INDICATIONS
For the management of moderately severe to severe essential hypertension and
in uncomplicated cases of malignant hypertension.
DOSAGE AND ADMINISTRATION
Therapy is usually started with one 2.5 mg tablet of INVERSINE (mecamylamine) twice a day.
This initial dosage should be modified by increments of one 2.5 mg tablet at
intervals of not less than 2 days until the desired blood pressure response
occurs (the criterion being a dosage just under that which causes signs of mild
postural hypotension).
The average total daily dosage of INVERSINE (mecamylamine) is 25 mg, usually in three divided
doses. However, as little as 2.5 mg daily may be sufficient to control hypertension
in some patients. A range of two to four or even more doses may be required
in severe cases when smooth control is difficult to obtain. In severe or urgent
cases, larger increments at smaller intervals may be needed. Partial tolerance
may develop in certain patients, requiring an increase in the daily dosage of
INVERSINE (mecamylamine) .
Administration of INVERSINE (mecamylamine) after meals may cause a more gradual absorption
and smoother control of excessively high blood pressure. The timing of doses
in relation to meals should be consistent. Since the blood pressure response
to antihypertensive drugs is increased in the early morning, the larger dose
should be given at noontime and perhaps in the evening. The morning dose, as
a rule, should be relatively small and in some instances may even be omitted.
The initial regulation of dosage should be determined by blood
pressure readings in the erect position at the time of maximal effect of the
drug, as well as by other signs and symptoms of orthostatic hypotension.
The effective maintenance dosage should be regulated by blood
pressure readings in the erect position and by limitation of dosage to that
which causes slight faintness or dizziness in this position. If the patient
or a relative can use a sphygmomanometer, instructions may be given to reduce
or omit a dose if readings fall below a designated level or if faintness or
lightheadedness occurs. However, no change should be instituted without
the knowledge of the physician.
Close supervision and education of the patient, as well as critical adjustment
of dosage, are essential to successful therapy.
Other Antihypertensive Agents
When INVERSINE (mecamylamine) is given with other antihypertensive drugs, the dosage of these
other agents, as well as that of INVERSINE (mecamylamine) , should be reduced to avoid excessive
hypotension. However, thiazides should be continued in their usual dosage, while
that of INVERSINE (mecamylamine) is decreased by at least 50 percent.
HOW SUPPLIED
Tablets INVERSINE (mecamylamine) , 2.5 mg, are slightly yellow, round compressed tablets, coded
LBS01. They are supplied as follows:
NDC 17205-0626-1 in bottles of 100.
Storage Condition
Store at 25°C (77°F); excursions permitted to 15-30°(59-86°F)
(see USP Controlled Room (Temperature)
Manufactured by: Siegfried CMS Ltd., Zofingen, Switzerland for
Targacept, Inc., Wmston-Salem, NC 27101. FDA revision date: 10/18/2002